Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions, Inc. (NASDAQ: BLFS) is a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. News about BLFS often centers on how its biopreservation media, CellSeal vials, hPL products, and related cell processing tools are used in clinical trials and commercial CGT therapies, as well as on portfolio changes and strategic transactions.
Investors and industry followers can use this page to track BioLife’s announcements on quarterly and annual financial results, including updates on Cell Processing revenue and the performance of its biopreservation media franchise. The company regularly reports on the contribution of customers with approved therapies, the extent of clinical trial adoption in the United States, and its use of GAAP and non-GAAP measures such as adjusted gross margin and adjusted EBITDA.
BioLife’s news flow also includes updates on portfolio streamlining and strategic moves, such as the divestiture of its evo cold chain logistics subsidiary and earlier sales of Global Cooling, SciSafe, and Custom Biogenic Systems, as well as acquisitions and investments like the PanTHERA CryoSolutions IRI cryopreservation technology and the strategic investment in Pluristyx. These items illustrate how the company is focusing on its core cell processing business while adding scientific capabilities and adjacencies.
In addition, BioLife issues press releases on corporate developments such as the opening of the Aby J. Mathew Center for Biopreservation Excellence in Bothell, Washington, and participation in healthcare and small- and mid-cap investor conferences. For readers following the CGT supply chain, this news page provides a centralized view of BioLife’s operational updates, clinical adoption metrics, strategic transactions, and investor communications over time.
BioLife Solutions reported record revenues for Q4 2022 at $44.4 million, up 19% year-over-year, and for the full year at $161.9 million, an increase of 36% from 2021. The company anticipates 2023 total revenue between $188 million and $202 million, reflecting growth of 16% to 25% over 2022, focused on its Cell Processing Platform, expected to contribute $89 million to $93 million. Management expects positive Adjusted EBITDA for 2022 and 2023.
BioLife Solutions (NASDAQ: BLFS) will announce preliminary 2022 revenue and 2023 guidance on January 9, 2023, prior to the J.P. Morgan Health Care Conference in San Francisco. CEO Michael Rice expressed confidence in the company's operational performance and plans to shift towards high-margin, recurring revenue streams. The company aims to position itself strongly within the cell and gene therapy market amidst increasing demand for biologic medicines. An updated investor presentation is also available on its corporate website.
BioLife Solutions, Inc. (Nasdaq: BLFS) announced its selection for the BioSpace Best Places to Work in Biopharma 2023 Report, recognizing its commitment to workplace flexibility, inclusion, and employee engagement. Following nominations from over 2,000 biopharma professionals, BioLife ranked among the top 60 companies, highlighting its strong company culture driven by teamwork and respect. CEO Mike Rice emphasized the importance of team members as the company's key asset, celebrating this recognition amid a competitive recruitment environment.
BioLife Solutions reported a record revenue of $40.7 million for Q3 2022, a 21% increase from Q3 2021, with biopreservation media revenue soaring 50%. Cash flow from operations was $1.5 million, and adjusted EBITDA stood at $1.4 million. The company tightens its 2022 revenue guidance, projecting a 34% to 38% year-over-year growth, driven by strong demand in its Cell Processing segment. Despite challenges due to supply-chain issues, 44% of total revenue came from proprietary consumables, affirming BioLife’s leadership in cell and gene therapies.
BioLife Solutions (NASDAQ: BLFS) will release its third quarter 2022 financial results after market close on November 9, 2022. A conference call and live webcast are scheduled for 4:30 PM ET the same day, where management will share financial insights and a business update. Investors can access the conference via the company's Investor Relations page. BioLife Solutions specializes in bioproduction tools and services aimed at cell and gene therapies, positioning itself as a key player in the biopharma sector.
CSafe has joined BioLife Solutions' global partner network to enhance cold chain solutions for cell and gene therapy (CGT). This partnership aims to support 10,000-12,000 evo shipments within the next year, catering to CGT products at various developmental stages. CSafe, with over 50 service centers worldwide, has a proven track record in temperature-controlled shipping, including solutions for billions of COVID-19 vaccine doses. The collaboration is expected to improve reliability, security, and service for CGT partners.
BioLife Solutions (NASDAQ: BLFS) has announced that Roderick de Greef, President and COO, will retire and return to the Board of Directors effective January 3, 2023. De Greef has served with the company for 22 years, steering significant operational improvements, notably in the ULT freezer product line. Geraint Phillips, previously Vice President of Freezer Operations, will take on the role of Senior Vice President, Global Operations. This transition is aimed at ensuring the continuity of leadership and operational success as the company grows.
BioLife Solutions (NASDAQ: BLFS) appointed Timothy L. Moore to its board of directors, enhancing its leadership. Moore, a seasoned executive with over 30 years in biopharmaceutical manufacturing, previously served as President and COO of PACT Pharma and held key roles at Kite Pharma and Genentech. His expertise is expected to guide BioLife in optimizing its marketing strategies and operational efficiency in the cell and gene therapy sectors.
BioLife Solutions reported record revenue of $40.5 million for Q2 2022, a 30% increase year-over-year with organic growth of 44%. Revenue guidance for 2022 has been updated to $160 million to $166 million, reflecting a year-over-year growth of 34% to 39%. Adjusted EBITDA was $1.5 million compared to a loss of $814,000 in Q1. Despite operational challenges, the biopreservation media segment achieved 46% growth. However, a non-cash impairment charge impacted financial results significantly, leading to a $72.6 million net loss for Q2.
BioLife Solutions, a supplier of bioproduction tools for cell and gene therapies, will announce its second quarter 2022 financial results after market close on August 9, 2022. A conference call and live webcast are scheduled for 4:30 PM ET, where management will discuss the financial results and provide a business update. The webcast can be accessed via the Investor Relations page on BioLife's website.